Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment

Bruijstens, A.L. (Arlette L), Blok, K.M. (Katelijn M), Smolders, J. (Joost), Wokke, B.H.A. (Beatrijs HA) and R.F. Neuteboom (Rinze)

2020-03-31

Additional Metadata
Persistent URL	doi.org/10.1177/1352458520921367, hdl.handle.net/1765/127220
Journal	Multiple Sclerosis: clinical and laboratory research
Organisation	Department of Neurology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Bruijstens, A.L. (Arlette L), Blok, K.M. (Katelijn M), Smolders, J. (Joost), Wokke, B.H.A. (Beatrijs HA), & Neuteboom, R. (2020). Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment. Multiple Sclerosis: clinical and laboratory research. doi:10.1177/1352458520921367

Publication